clinical trial · NCT06074549
DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Coronary Bioadaptor System
Elixir Medical Corporation·—·recruiting·n = 5,000
Coronary Artery DiseaseDynamX Novolimus-eluting Coronary Bioadaptor System
brief summary
The goal of this registry is to confirm the safety, and performance of the DynamX Coronary Bioadaptor System in patients with coronary artery disease.
started
Mar 10, 2024
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Aug 28, 2025
detailed description
This registry will obtain additional safety, effectiveness, and performance data on the DynamX Coronary Bioadaptor System in the treatment of patients with ischemic heart disease due to de novo native coronary artery lesions in a real-world patient population.
official title
DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Coronary Bioadaptor System (Bio-RESTORE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol